Valuing IP portfolios for pharmaceuticals and medical devices

BVWireIssue #75-2
December 10, 2008

With billions spent on medical research and many billions more generated in revenues from resulting patents, it is no wonder there are disputes in the pharmaceutical and medical device industry over lucrative intellectual property assets and often widely disparate views on their value. 

As any BV practitioner knows, the ins-and-outs of healthcare valuation are full of potential pitfalls.  In our 100-minute teleconference, Pharmaceuticals & Medical Devices: Building & Valuing Intellectual Property Portfolios, Mike Pellegrino of Pellegrino & Associates and Dustin DuBois with the law firm of Ice Miller will tackle the unique challenges in pharmaceutical and health care patents.  Among other things, attendees will learn how to wade through the science to get to the value proposition, develop an understanding of the regulatory process and its impact on value, and meet the unique challenges in the pharmaceutical and medical device space.  The event—which includes a live Q&A—will take place on Thursday, December 11, 2008 at 1 p.m. Eastern time. For more information, click here.

Please let us know if you have any comments about this article or enhancements you would like to see.